This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
rsi: Archive
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
by Zacks Equity Research
Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
DYNPositive Net Change
rsi stock-price-movement
California BanCorp (BCAL) Loses -10.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
California BanCorp (BCAL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BCALNegative Net Change
rsi stock-price-movement
After Plunging -12.62% in 4 Weeks, Here's Why the Trend Might Reverse for RLI Corp. (RLI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for RLI Corp. (RLI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RLIPositive Net Change
rsi stock-price-movement
Down -8.23% in 4 Weeks, Here's Why American States Water (AWR) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for American States Water (AWR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AWRNegative Net Change
rsi stock-price-movement
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
by Zacks Equity Research
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ZURANegative Net Change
rsi stock-price-movement
CNX Resources (CNX) Loses -20.28% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
CNX Resources (CNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CNXPositive Net Change
rsi stock-price-movement
Down -6.25% in 4 Weeks, Here's Why Murphy USA (MUSA) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Murphy USA (MUSA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
MUSAPositive Net Change
rsi stock-price-movement
After Plunging -17.36% in 4 Weeks, Here's Why the Trend Might Reverse for Fluence Energy (FLNC)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Fluence Energy (FLNC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FLNCNegative Net Change
rsi stock-price-movement
After Plunging -9.7% in 4 Weeks, Here's Why the Trend Might Reverse for Chipotle (CMG)
by Zacks Equity Research
Chipotle (CMG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CMGNegative Net Change
rsi stock-price-movement
Down -22.21% in 4 Weeks, Here's Why You Should You Buy the Dip in Calumet, Inc. (CLMT)
by Zacks Equity Research
Calumet, Inc. (CLMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CLMTPositive Net Change
rsi stock-price-movement
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
by Zacks Equity Research
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
XNCRNegative Net Change
rsi stock-price-movement
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
by Zacks Equity Research
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ERASNo Net Change
rsi stock-price-movement
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Repare Therapeutics (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
RPTXNo Net Change
rsi stock-price-movement
Down -5.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Definitive Healthcare (DH)
by Zacks Equity Research
Definitive Healthcare (DH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
DHPositive Net Change
rsi stock-price-movement
Down -6.89% in 4 Weeks, Here's Why Murphy USA (MUSA) Looks Ripe for a Turnaround
by Zacks Equity Research
Murphy USA (MUSA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MUSAPositive Net Change
rsi stock-price-movement
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Keros Therapeutics (KROS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
KROSNegative Net Change
rsi stock-price-movement
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
by Zacks Equity Research
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
XNCRNegative Net Change
rsi stock-price-movement
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
by Zacks Equity Research
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ERASNo Net Change
rsi stock-price-movement
Malibu Boats (MBUU) Loses -5.16% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Malibu Boats (MBUU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MBUUNegative Net Change
rsi stock-price-movement
Down -9.36% in 4 Weeks, Here's Why InterDigital (IDCC) Looks Ripe for a Turnaround
by Zacks Equity Research
InterDigital (IDCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
IDCCNo Net Change
rsi stock-price-movement
ZIM (ZIM) Loses -9.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for ZIM (ZIM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZIMPositive Net Change
rsi stock-price-movement
Here's Why America's Car-Mart (CRMT) is Poised for a Turnaround After Losing -15.1% in 4 Weeks
by Zacks Equity Research
America's Car-Mart (CRMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CRMTNegative Net Change
rsi stock-price-movement
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
by Zacks Equity Research
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ERASNo Net Change
rsi stock-price-movement
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Revolution Medicines (RVMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RVMDNegative Net Change
rsi stock-price-movement
Here's Why Kura Sushi (KRUS) is Poised for a Turnaround After Losing -13.55% in 4 Weeks
by Zacks Equity Research
Kura Sushi (KRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
KRUSPositive Net Change
rsi stock-price-movement